Presentations
Steeg T.v., Bergmann K., huang Q., Sachsenmeier K. and Agoram B., Does it take two or four to tango? Modeling & simulation of bispecific antibodies in oncology. Noordwijkerhout.(2014)
Snelder N., Ploeger B., Luttringer O., Rigel D., Webb R., Feldman D., Fu F., Beil M., Jin L., stanski D. and Danhof M., Characterization and prediction of cardiovascular effects of S1P receptor agonists; a Systems pharmacology modeling approach. Noordwijkerhout.(2014)
Snelder N., Ploeger B., Luttringer O., Rigel D., Webb R., Feldman D., Fu F., Beil M., Jin L., stanski D. and Danhof M., Characterization and prediction of cardiovascular effects of S1P receptor agonists; a Systems pharmacology modeling approach. Noordwijkerhout.(2014)
Bergmann K., Fairman D. and Vis P., Mechanism based PK/PD model for the effect of rhLCAT and apoA-I preparations on reverse cholesterol transport. Noordwijkerhout.(2014)
Maanen E.v., Steeg T.v., Stone J., Dobrowolska J., Michener M., Savage M., Kennedy M., Bateman R., Kleijn H. and Danhof M., A systems pharmacology model accounting for tracer dynamics throughout the APP pathway: Implications for interpretation of BACE inhibition response in CMP rhesus monkeys. Noordwijkerhout.(2014)
Maanen E.v., Steeg T.v., Stone J., Dobrowolska J., Michener M., Savage M., Kennedy M., Bateman R., Kleijn H. and Danhof M., Integrating tracer kinetic data with absolute protein concentration measurements in a systems pharmacology model. Application to the APP pathway in CMP rhesus monkeys., PAGE.(2014) [Link to publication]
Maanen E.v., Ackaert O., Haddish-Berhane N., Snelder N., Jongh J.d., Barton H. and Betts A., A new model-based approach to compare toxicity of a series of compounds based on their categorical toxicity scores. PAGE.(2014) [Link to publication]
Ackaert O., Steeg T.v., Hannesdottir K., Alexander R., Raudibaugh K., Kugler A. and Vis P., Quantification of the effect of AZD5213 on sleep in patients with Alzheimer’s disease or mild cognitive impairment using a two-state Markov model. PAGE.(2014) [Link to publication]
Stringer F., Matsuno K., Snelder N. and Hirayama M., A Semi-Mechanistic Modeling approach to support Phase III dose selection for TAK-875 Integrating Glucose and HbA1c Data in Japanese Type 2 Diabetes Patients. PAGE.(2013) [Link to publication]
Stringer F., DeJongh J., Scott G. and Danhof M., A population PK-PD model for effects of Sipoglitazar on FPG and HbA1c in patients with type II diabetes. PAGE.(2013) [Link to publication]